Blas MJ

Idioma: Español
Referencias bibliográficas: 40
Paginas: 58-62
Archivo PDF: 128.85 Kb.

RESUMEN

El uso de los corticoesteroides como parte del tratamiento en pacientes con sepsis o en choque séptico ha sido controversial por décadas. En el pasado se llegó al consenso de que las dosis farmacológicas de esteroides no debían de ser utilizadas tanto en pacientes con sepsis como en choque séptico porque no incrementaban la supervivencia y sí podrían aumentar la morbimortalidad. Estudios actuales han mostrado resultados positivos, con evidencia de una reducción de la mortalidad en pacientes con sepsis o choque séptico. Varios efectos de los esteroides podrían explicar los resultados actuales, entre ellos el tratamiento de una insuficiencia adrenal “relativa”, el aumento en la reactividad de los receptores y su bien conocido efecto antiinflamatorio. Sin embargo, antes de hacer cualquier recomendación para su uso en la clínica habrán de recabarse más estudios sólidos que confirmen lo anterior.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Shoemaker WC, Shapiro L, Gelfand AJ. Citocinas en la enfermedad. En: Shoemaker WC, Ayress, Grennika, Holbrook RR, editores. Tratado de Medicina Critica y Terapia Intensiva 4 ed, Argentina: Panamericana, 2002:562-565.

2. Flores UD. Fisiopatología del estado de choque. En: Díaz de Leon M, Aristondo MG, Briones Garduño JC, editores. Medicina Crítica Diagnóstico y Terapéutica, México: Editora Mexicana, 2001:97-111.

3. Munford SR. Sepsis y shock séptico En: Wilson JD, Braunwald E, Isselbacher RJ, editores, Harrison, Principios de Medicina Interna, 14 ed, Argentina McGraw-Hill 2000:885-890.

4. Bone RC, Fisher CJ Jr, Clemmer TP et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-658.

5. The veterans administration systemic sepsis cooperative study group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-655.

6. Sprung CL, Caralis PV, Marcial EG. The effects of high-dose corticosteroids in patients with septic shock: A prospective controlled study. N Engl J Med 1984;311:1137-1143.

7. Luce JM, Montgomery AB, Marks JD et al. Ineffectiveness of high-doses methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988;138:62-68.

8. Bone RC, Fisher CJ Jr, Clemmer TP et al. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987;92:1032-1036.

9. Lucas CE, Ledgerwood AM. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg 1984;119:537-541.

10. Shumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333-341.

11. Klatersky J. Cappel R, Debusscer L. Effectiveness of betamethasone in management of severe infections. N Engl J Med 1971;284:1248-1250.

12. Cooperative Study Group. The efectiveness of hydrocortisone in the management of severe infection. JAMA 1963;183:462-465.

13. Slotman GJ, Fisher CJ Jr, Bone RC et al. Detrimental effect of high-dose methyprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. Crit Care Med 1993;21:191-195.

14. Thompson WL, Garley HT, Lutz BA et al. Inefficacy of glucocorticoids in shock (double-blind study). Abstr Clin Res 1976;24:25A.

15. Hoffman SL, Punjabi NH, Kumala S et al. Reduction of mortality in chloramphenicol treated severe thyroid fever by high dose dexamethasone. N Engl J Med 1984;310:82-88.

16. Odio CM, Faingezicht I, Paris M et al: The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991;324:1521-1531.

17. Montaner JS, Lawson LM, Levitl N et al. Corticosteroids prevent early deterioration in patients with moderate severe Pneumocystis carinii pneumonia and the acquired Immunodeficiency syndrome. Ann Intern Med 1990;113:14-20.

18. Meduri GN, Chinn AJ, Lefer KN et al. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS: Patterns of response and predictors of outcome. Chest 1994;105:1516-1527.

19. Hammerschmidt DE, White JG, Craddock PR et al. Corticosteroids inhibit complement-induced granulocyte aggregation: A possible mechanisms for their efficacy in shock states. J Clinic Invest 1979;63:798-803.

20. Haupt MT, Jastremski MS, Clemmer TP et al. Effect of ibuprofen in patients with severe sepsis: A randomized double-blind multicenter study. Crit Care Med 1991;19: 1339-1347.

21. Bernard GB, Wheeler AP, Russell JA et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997;336:912-918.

22. Fisher CJ, Slotman GJ, Opal SM. Recombinant human interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12-21.

23. Fisher CJ, Dhainant JF, Opal SM. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994;271:1836-1840.

24. Abraham E, Wunderink R, Silverman H. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 1995;273: 934-941.

25. Panacek EA, Marshall J, Fichkoff S et al. Neutralization of TNF by a monoclonal antibody omproves survival and reduces organ dysfunction in human sepsis: Results of the MONARCS trial. Chest 2000;18:885(abstr).

26. Fein AM, Bernard GR, Criner GJ et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (cp0127). JAMA 1997;277:482-487.

27. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis, N Engl J Med 2001;344:699-709.

28. Zeni F, Freeman B, Natansonm CH, Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997;25:1095-1100.

29. Montaner JS, Lawson LM, Levitt N et al. Corticosteroids prevent early deterioration in patients with moderate severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome. Ann Intern Med 1990;113:14-20.

30. Gagnon S, Boota AM, Fischl MA et al. Corticosteroids as adjuntive therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1990;113:14-20.

31. Bollaert PE, Charpentier C, Levy S et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-650.

32. Briegel J, Forst H, Haller M et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective randomized double-blind, single center study. Crit Care Med 1999;27:723-732.

33. Amane D et al. Effects of the combination of hydrocortisone (HC) and flucortisone (FC) on mortality in septic shock. Crit Care Med 2000;28:46.

34. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and suvirval in septic shock. Lancet 1991;337:582-583.

35. Vincent JL, Zhang H, Szabo C et al. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med 2000;161:17.

36. Saito T, Takanashi M, Gallager E et al. Corticosteroids effects on early beta-adrenergic down-regulation during circulatory shock: Hemodinamyc, study and beta-adrenergic receptor assay. Intensive Care Med 1995;21:204-210.

37. Auphan UJ, Di Donato C, Rosette A et al. Immunosuppression by glucocorticoids, inhibition of NF-kB activity through induction of IKB-alpha synthesis. Science 1995; 270:286-290.

38. Blackwell TS, Blackwell TR, Holden EP et al. In vivo antioxidant treatment suppresses nucler factor KB activation and neutrophilic lung inflammation. J Immunol 1996;157: 1630-1637.

39. Le Tulzo Y, Shenkar R, Kaneko D et al. Hemorrhage increases cytokine expression in lung mononuclear cells mice: Involvement of catecholamines in nuclear factor (NF)-kB regulation and cytokine expression. J Clin Invest 1997;99:1516-1524.

40. George CL, Fantuzzi G, Bursten S et al. Effects of lisofylline on hyperoxia induce lung injury. Am J Immunol 1999;276:L776-L785.